These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6392091)

  • 21. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.
    Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Pournaras S; Markou F
    J Antimicrob Chemother; 2007 Jul; 60(1):136-9. PubMed ID: 17491004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular nature of a drug resistance factor in Proteus mirabilis.
    Van Rensburg AJ
    S Afr Med J; 1972 Feb; 46(9):200-2. PubMed ID: 4552782
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies on heavy-metal resistance in clinical isolates of Proteus mirabilis.
    Nakahara H; Asakawa M; Yonekura I; Sato A; Ohshima K; Kitamura M
    Nihon Eiseigaku Zasshi; 1984 Dec; 39(5):812-8. PubMed ID: 6398376
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasmid-mediated multiple antibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection.
    Khan AU; Musharraf A
    Med Sci Monit; 2004 Nov; 10(11):CR598-602. PubMed ID: 15507850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Transmission of the R-plasmids and expression of their genes in Proteus mirabilis].
    Kuptsova NV
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Sep; (9):106-14. PubMed ID: 339619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative characteristics of the biological properties of Proteus varieties].
    Vitvitskiĭ VM; Fedorina AP; Godun VM
    Mikrobiol Zh; 1976; 38(2):205-7. PubMed ID: 781487
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
    Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
    Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibiotic activity in relation to various Proteus species].
    Kazanovskiĭ AM
    Farm Zh; 1975; 30(3):79-83. PubMed ID: 767133
    [No Abstract]   [Full Text] [Related]  

  • 29. Transduction of R factors in Proteus mirabilis and P. rettgeri.
    Coetzee JN; Datta N; Hedges RW; Appelbaum PC
    J Gen Microbiol; 1973 Jun; 76(2):355-68. PubMed ID: 4579129
    [No Abstract]   [Full Text] [Related]  

  • 30. [Molecular characterization of plasmids of Proteus rettgeri].
    Barbuti S; Tovagliari D; Somenzi P; Toni M
    Boll Ist Sieroter Milan; 1981 May; 60(2):89-94. PubMed ID: 7306392
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of mupirocin at subinhibitory concentrations on flagella formation in Pseudomonas aeruginosa and Proteus mirabilis.
    Horii T; Morita M; Muramatsu H; Muranaka Y; Kanno T; Maekawa M
    J Antimicrob Chemother; 2003 May; 51(5):1175-9. PubMed ID: 12697640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dynamics of drug resistance in Proteus mirabilis cultures 1970-1985].
    Shvidenko IG
    Antibiot Khimioter; 1988 Apr; 33(4):294-7. PubMed ID: 3291802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteus mirabilis clinical isolate harbouring a new variant of Salmonella genomic island 1 containing the multiple antibiotic resistance region.
    Ahmed AM; Hussein AI; Shimamoto T
    J Antimicrob Chemother; 2007 Feb; 59(2):184-90. PubMed ID: 17114173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ulcer infection by ESbetaL-producing Proteus mirabilis: a case report.
    Savini V; Catavitello C; Talia M; Di Berardino F; Manna A; Balbinot A; Febbo F; Carlino D; Fioritoni F; Di Bonaventura G; D'Antonio D
    Int J Low Extrem Wounds; 2008 Jun; 7(2):99-101. PubMed ID: 18483010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The in vitro effects of cephalothin, gentamicin and their combination against Proteus mirabilis and Enterococci].
    Lode H; Naumann P
    Adv Clin Pharmacol; 1974; 8():46-50. PubMed ID: 4619756
    [No Abstract]   [Full Text] [Related]  

  • 36. Envelope alterations produced by R factors in Proteus mirabilis.
    Hesslewood SR; Smith JT
    J Gen Microbiol; 1974 Nov; 85(1):146-52. PubMed ID: 4612103
    [No Abstract]   [Full Text] [Related]  

  • 37. Proceedings: Sensitivity of R+ strains of Proteus mirabilis to sodium desoxycholate.
    Hesslewood SR
    J Pharm Pharmacol; 1974 Dec; 26 Suppl():96P-97P. PubMed ID: 4156781
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro susceptibility of the skin infections bacterium to some antimicrobial agents].
    Shimizu M; Nishii M; Shida Y; Hattori T
    Jpn J Antibiot; 1983 Feb; 36(2):290-2. PubMed ID: 6406720
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antimicrobial susceptibility of Proteus mirabilis urinary tract isolates from 1999 to 2005 at Nîmes University Hospital].
    Mahamat A; Lavigne JP; Bouziges N; Daurès JP; Sotto A
    Pathol Biol (Paris); 2006; 54(8-9):456-61. PubMed ID: 17030456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.